Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript
Design Therapeutics, Inc. (DSGN) held its Q1 2026 earnings call on April 28, 2026, during which the company reported an EPS of -$0.29, beating estimates by $0.04, with no revenue for the quarter. The company provided a general update on its Friedreich’s ataxia (FA) program and the ongoing RESTORE-FA clinical trial, emphasizing its focus on multiple biomarker endpoints. CEO Pratik Shah highlighted forward-looking statements regarding the company's R&D efforts, business outlook, and financial condition, noting the inherent risks and uncertainties involved.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4896405-design-therapeutics-inc-dsgn-q1-2026-earnings-call-prepared-remarks-transcript"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
